Highlights•Five nucleoside inhibitors of HBV polymerase have been approved for clinical
use.•HBV polymerase protein priming activity is inhibited by purine analogs.•Entecavir and …

Hepatitis B virus (HBV) infection is a major cause of acute and chronic hepatitis, and of its
long-term complications. It is the most variable among DNA viruses, mostly because of its …

Chronic infection with the hepatitis B virus (HBV) affects an estimate of 240 million people
worldwide despite the availability of a preventive vaccine. Medication to repress viral …

Hepatitis B virus (HBV) has a worldwide distribution and is endemic in many populations.
Due to its unique life cycle which requires an error-prone reverse transcriptase for …

Despite the availability of effective vaccination, hepatitis B virus (HBV) infection continues to
be a major challenge worldwide. Research efforts are ongoing to find an effective cure for …

Tenofovir (TDF) is considered the ideal treatment for patients coinfected with human
immunodeficiency virus (HIV) and hepatitis B virus (HBV). However, certain coinfected …

The hepatitis B virus (HBV) is a global public health problem with more than 240 million
people chronically infected worldwide, who are at risk for end-stage liver disease and …

Hepatitis B virus (HBV) affects more than 257 million people globally, resulting in
progressively worsening liver disease, manifesting as fibrosis, cirrhosis, and hepatocellular …

Infection with HBV is common worldwide, with over 350 million chronic carriers. Chronic
HBV infection is associated with cirrhosis and hepatocellular carcinoma. All currently …

Hepatitis B virus (HBV) quasispecies contain a large number of variants that serve as a
reservoir for viral selection under antiviral treatment and the immune response, leading to …